<DOC>
<DOCNO>EP-0634411</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Process for the preparation of 8- 4'-[4"-(pyrimidin-2'''-yl)-piperazin-1''-yl]-butyl -8-aza-spiro[4,5]
decan-7,9-dione and of its hydrochlorides of high purity
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D29500	C07B6100	B01J2502	C07D22100	C07D23900	A61K31505	B01J2344	C07D23900	C07D24100	C07B6100	A61K31505	B01J2344	A61P2520	A61K31445	C07D40114	C07D40112	A61K31445	C07D40100	A61P2500	C07D24100	C07D22120	B01J2500	C07D29500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07B	B01J	C07D	C07D	A61K	B01J	C07D	C07D	C07B	A61K	B01J	A61P	A61K	C07D	C07D	A61K	C07D	A61P	C07D	C07D	B01J	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D295	C07B61	B01J25	C07D221	C07D239	A61K31	B01J23	C07D239	C07D241	C07B61	A61K31	B01J23	A61P25	A61K31	C07D401	C07D401	A61K31	C07D401	A61P25	C07D241	C07D221	B01J25	C07D295	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to a process for the preparation of 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]
d ecan e-7,9-dione {buspirone} of the formula 
<
IMAGE
>
 and of its hydrochlorides by hydrogenating 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]but-2'-ynyl}-8-azaspiro [4.5 ]
decane-7,9-dione of the formula 
<
IMAGE
>
 in the presence of a palladium or Raney nickel catalyst in an organic solvent and optionally converting the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]
d ecan e-7,9-dione into a hydrochloride, in which a solution of 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]but-2'-ynyl}-8-azaspiro [4.5 ]
decane-7,9-dione of the formula II in an organic solvent whose concentration is at least 40% by weight is added to a suspension of the catalyst in an organic solvent, the catalyst is removed and   a) the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]
d ecan e-7,9-dione base of the formula I is isolated and/or b) the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]
d ecan e-7,9-dione base of the formula I is treated with hydrogen chloride at 15 to 40 DEG C in ethanol or isopropanol and the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]
d ecan e-7,9-dione hydrochloride melting at 188 to 191 DEG C is isolated or c) the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]
d ecan e-7,9-dione base of the formula I is treated at at most 70 DEG C with hydrogen chloride in ethyl acetate or isopropanol and the 8-{4'-[4''-(pyrimidin-2'''-yl)piperazin-1''-yl]butyl}-8-azaspiro[4.5]
d ecan e-7,9-dione hydrochloride melting at 201 to 203 DEG C is isolated.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
A process for the production of 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane-7,9-dione-{buspirone}having
the formula



and of the high purity hydrochlorides thereof by catalytic hydrogenation of 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-but-2'-inyl}-8-aza-spiro[4,5]
decane-7,
9-dione having

the formula


in the presence of a palladium or Raney nickel catalyst in an inert organic solvent and optionally
subsequently converting said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

obtained into a hydrochloride, characterized by continuously
adding a solution of 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-but-2'-inyl}-8-aza-spiro[4,5]decane-7,9-dione

of formula II in an inert organic solvent, the concentration
of which is at least 40 % by weight/ % by weight, to a suspension of the catalyst in an inert

organic solvent, removing said catalyst and thereafter

a) isolating said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane
7,9-dione base of formula I, and/or
b) treating said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane-7,9-dione
base of formula I at a temperature of 15 to 40°C in ethanol or isopropanol

with hydrogen chloride with stirring, and isolating the 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane-7,9-dione
hydrochloride

melting from 188 to 191°C, or 
c) treating said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane-7,9-dione
base of formula I at a temperature of at maximum 70°C in ethyl

acetate or isopropanol with hydrogen chloride with stirring, and isolating said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

hydrochloride
melting from 201 to 203°C.
A process according to claim 1, characterized in that a solution with a concentration of 40
to 70 % by weight/% by weight of 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-but-2'-inyl}-8-aza-spiro[4,5]decane-7,9-dione

of formula II is used.
A process according to claim 1 or 2, characterized in that for the solution of said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-but-2'-inyl}-8-aza-spiro[4,5]
decane-7,9-dione
of formula

II a polar protic and/or an apolar aprotic and/or a polar aprotic one is used as a solvent.
A process according to any one of claims 1 to 3, characterized in that for the solution of 8-{4'-[4"(pyrimidine-2'''-yl)-piperazine-1"-yl]-but-2'-inyl}-8-aza-spiro[4,5]
decane-7,9-dione
of formula II methanol, ethanol, benzene, and/or tetrahydrofuran is used as a solvent.
A process according to any one of claims 1 to 4, characterized in that for the suspension of
palladium or Raney nickel catalyst methanol, ethanol, benzene, and/or tetrahydrofuran is

used as an inert solvent.
A process according to any one of claims 1 to 5, characterized in that, as a palladium catalyst,
there is used one which is applied onto a carrier, especially coal.
A process according to any one of claims 1 to 6, characterized in that for the solution of 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-but-2'-inyl}-8-aza-spiro[4,5]
decane-7,9-dione
of formula II there is used the same solvent as for the suspension of the catalyst.
A process according to any one of claims 1 to 7, characterized in that the solution of 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-but-2'-inyl}-8-aza-spiro[4,5]
decane-7,
9-dione of

formula II is added continuously to the suspension of the catalyst at such a rate that the
weight ratio of 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-but-2'-inyl}-8-aza-spiro[4,5]decane-7,9-dione

of formula II to the catalyst is /0.01 to 1/ : 1. 
A process according to any one of claims 1b) or 2 to 8, characterized in that the treatment
of said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

base of formula I is carried out in ethanol or isopropanol with hydrogen chloride for
the production of said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

hydrochloride having a melting point from 188° to 191°C at a temperature
of about 20°C.
A process according to any one of claims 1c) or 2 to 8, characterized in that the treatment
of said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

base of formula I is carried out in ethyl acetate or isopropanol with hydrogen chloride
for the production of said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

hydrochloride having a melting point from 201 to 203°C at a
temperature of 40 to 65°C, especially at about 60°C.
A process according to any one of claims 1b) or 1c) or 2 to 10, characterized in that said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane-7,9-dione
base

of formula I is used for the conversion into said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane-7,9-dione
hydrochloride in the form of said 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

base of formula
I containing solution being obtained after removing the catalyst.
A process according to any one of claims 1b) or 1c) or 2 to 11, characterized in that the
addition of hydrogen chloride-containing ethanol or isopropanol or ethyl acetate, respectively,

to 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]-butyl}-8-aza-spiro[4,5]
decane-7,9-dione
base of formula I for the conversion into 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
butyl}-8-aza-spiro[4,5]decane-7,9-dione

hydrochloride is performed for 5 to 30 minutes.
A process according to any one of claims 1b) or 1c) or 2 to 12, characterized in that the
stirring while treating the 8-{4'-[4"-(pyrimidine-2'''-yl)-piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

base of formula I in ethanol or isopropanol or ethyl acetate, respectively,
with hydrogen chloride for the production of said 8-{4'-[4"-(pyrimidine-2'''-yl)piperazine-1"-yl]
-butyl}-8-aza-spiro[4,5]decane-7,9-dione

hydrochloride is performed for 1
to 5 hours.
</CLAIMS>
</TEXT>
</DOC>
